Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Vascul Pharmacol. 2015 Jul 26;76:42–52. doi: 10.1016/j.vph.2015.07.011

Figure 11.

Figure 11

HCAECs were maintained in EBM-2 alone (Control) or EBM-2 containing tunicamycin (“Tun”, 10 μg/ml, 30 min) or thapsigargin (“Thaps”, 1 μM, 10 min) and in the presence or absence of the TRPC3 selective blocker Pyr10 (2 μM), as indicated. Following treatments, cells were processed for immunodetection of phospho-CAMKII (Thr286; ~50 kDa) in whole cell lysates. Membranes were reprobed for GAPDH (~37 kDa) to control for protein loading.